Publications | PubMed=25939062; DOI=10.1038/nm.3855; PMCID=PMC4862411 Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N., Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J., Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C., Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L., Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J., Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J., Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N., Keller C., Pal R., Grill J., Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21:555-559(2015) PubMed=26115193; DOI=10.1097/NEN.0000000000000216; PMCID=PMC4596247 Taylor I.C., Hutt-Cabezas M., Brandt W.D., Kambhampati M., Nazarian J., Chang H.T., Warren K.E., Eberhart C.G., Raabe E.H. Disrupting NOTCH slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition. J. Neuropathol. Exp. Neurol. 74:778-790(2015) PubMed=28823557; DOI=10.1016/j.cell.2017.07.016; PMCID=PMC5587159 Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A., Jones C., Vogel H., Jackson P.K., Monje M. Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma. Cell 170:845-859.e19(2017) PubMed=31439867; DOI=10.1038/s41467-019-11732-6; PMCID=PMC6706443 Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L., Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C., Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nat. Commun. 10:3790.1-3790.10(2019) PubMed=33319914; DOI=10.1093/gigascience/giaa136; PMCID=PMC7736793 Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M., Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I., Haussler D., Salama S.R., Vaske O.M. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma. GigaScience 9:giaa136.1-giaa136.14(2020) PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809 He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N., Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J., Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J., Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P., Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M., Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z., Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J. Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nat. Commun. 12:4089.1-4089.17(2021) PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061 Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. Acta Neuropathol. Commun. 9:178.1-178.12(2021) |